Edward Lichten, M.D.,PC
555 South Old Woodward Suite #700
Birmingham, MI 48009 
Email: drlichten@yahoo.com



"Why You Can't Lose those
Last 10 Pounds."


Print this Article


Since 1950, there has been an explosion of chronic disease in both children and adults. The White House Task Force on Childhood Obesity and F.D.A. papers on the increase in childhood asthma, cancers and attention deficient disorders mentions/ implies a direct link to endocrine-disrupting chemicals (EDC).  The EDC are present in the trenbulone pellets used to fatten cattle, the estradiol found in hen’s eggs, the oraganophosphates (DDT-like pesticides) sprayed on fruits and vegetables and the bisphenol-A that leaks out of plastic containers.1  Rachel Casson predicted our present/future healthcare disaster in Silent Spring published in 1962.2



While the F.D.A. is collecting data and computer modeling3, European and American researchers have found that these endocrine-disrupting chemicals (EDC) bind to human Sex Hormone Binding Globulin (hSHBG).  These compounds and their derivatives have great affinity (potency) to induce hormonal changes in the human species.4



Focusing on SHBG measurements for the last 20 years, Lichten found a strong correlation between dysfunctional SHBG levels and disease in men, specifically diabetes5 and heart disease6. The normal range of SHBG in men was 5-15 nmol/l in 1972.6 Since increased “SHBG is an Estrogen amplifier6,” increases or decreases in SHBG  interfere with normal testosterone effects and are contra-productive to homeostatic male health. Lichten found an F.D.A. approved pharmacologic agent that blocks SHBG production.



Lichten recognized that elevated SHBG was reducing bio-available testosterone (bio-T), so he reasoned that blocking SHBG production would increase bio-T.  Surprisingly, the reduction of SHBG was linked to dramatic improvements in diabetes: men often reduced their insulin requirements by 50 percent, and discontinued their oral diabetic medications altogether.  Lichten had anticipated and answered Harvard’s EL Ding’s query8 10 years earlier: “The clinical usefulness of both SHBG genotypes and plasma levels in stratification and intervention for the risk of type 2 diabetes warrants further examination.”  

Court documents show that Lichten’s I.R.B. research protocol9 through the Ascension Health Hospital System was summarily closed and never allowed to reopen after the results were made known to the administration. 


While two European research groups 10-11 have published data showing that testosterone can improve diabetic control in men, the key role of blocking  excessive SHBG simultaneously has been Lichten’s work alone.  And, recognizing endocrine-disrupting chemicals (EDC ) cause increases in SHBG  makes the Pharmaceutical- Insurance – Government – Special (Hospital) Interest groups more than just notice.



Starting in 2004, Blue Cross and Blue Shield of Michigan (BCBSM) stopped paying Lichten’s patients for healthcare received in Doctor Lichten’s office.  The litigation claims that these actions violate numerous state and federal statues. Letters to the Michigan Attorney General, Office of Financial and Insurance Regulation, local, state and national medical associations including the AMA were ignored or replied to as they “don’t get involved in these matters.”



The www.USDOCTOR.com website lists almost 50 chronic medical diseases in both men and women that Lichten reports may improve/ respond to the I.R.B. protocol of normalizing SHBG and thereby,  blocking these EDC s.  There will be more diseases that may well respond to the I.R.B. protocol as  it gains more contributing physicians:


Anemia (dialysis related), Arthritis, Breast Cancer post treatment hot flashes, Cardiomyopathy, Chronic Fatigue and Fibromyalgia, Crohn’s and ulcerative colitis, Depression, Diabetes (insulin and non-insulin requiring), Endometriosis,  post-Myocardial Infarction, Reflux Sympathetic Dystrophy, Menstrual migraine and seizures, Premenstrual syndrome, Erectile Dysfunction, Low Testosterone, Female Sexual Dysfunction, Fibroid uterine tumors (leiomyomata), Lupus erythematosis, Menstrual pain,  Osteoporosis, profuse menstrual bleeding, Migraine in men, Deep vein thrombophlebitis, Restless Leg syndrome, Sjogren’s dry eyes, …...



Lichten has gone through an independent I.R.B. to resume his research. Clinically, Lichten and the peer reviewed medical literature show low levers of testosterone and dysfunctional levels of SHBG are found in men who suffer with diabetes12, , osteoporosis, aortic aneurysm, Alzheimer’s disease, heart disease,  and other disease states…..


Likewise, treatment to normalize SHBG has often resulted in dramatic improvement in the disease process.  As thousands of physicians can now join in the I.R.B. protocol, this project has the potential to dramatically influence health care and wellness.  Since these inexpensive, generic hormones used in the I.R.B. protocol are cheaper, safer and often offer better results than the expensive biologic and pharmaceutical agents now promoted by the Pharmaceutical- Insurance – Government – Special (Hospital) Interest groups, billions of dollars are potentially to be lost: IF THE TRUTH BECOMES KNOWN.


Email a copy of this article to a friend: http://www.USDOCTOR.com/WSJ




1. Stephany RW. Hormonal growth promoting agents in food producing animals. Handbook Experimental Pharmacology  2010;(195):355-67   PMID: 20020373

2. Casson, Rachel. Silent Spring. Houghton Mifflin.

3. F.D.A.  U.S. Food and Drug Administration: Endocrine Disruptors Knowledge Base http://www.fda.gov/ScienceResearch/BioinformaticsTools/EndocrineDisruptorKnowledgebase/default.htm

4. Bauer ER, et al. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. APMIS 2000 Dec; 108(12):838-46.  PMID: 11252818

5. SHBG and diabetes

6. SHBG and heart disease in men

7. Anderson DC. SHBG is an Oestrogen Amplifier. Nature. 1972; 240: 38-40

8. Ding EL, et al.  Sex-hormone binding globulin and risk of type 2 diabetse in women and men. New England Journal of Medicine. 2009; Sept 17; 361(12): 527-33 PMID: 19657112

9. Lichten, E.M. Providence Hospital, Southfield, Michigan. Protocol 601-97.

10. Kapoor D.  Testosterone Replacement Therapy Improves Insulin Resitance, Glycemic Control, visceral Adiposity and Hypercholesterolemia in Hypogonadal Men with Type 2 Diabetes. European Journal of Endocrinology. 2006; 154(6): 899-906.

11.   Huefelder AE. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. Journal of Andrology 2009 Nov-Dec;30(6):726-33. Epub 2009 Jul 3. PMID: 19578132

12. Lakshman KM, Bhasin S, et al. Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men. Journal of Gerontology Series A: Biologic Science and Medical Science 2010 May;65(5):503-9. Epub 2010 Jan 27. PMID: 20106959

 13. Why you Can't Lose those Last 10 pounds.    Yahoo shine. 2010          http://shine.yahoo.com/event/loveyourbody/why-you-cant-lose-those-last-10-pounds-1964849/print/;_ylt=ApqdzOw7beqWVcviEIMYh1pNhaU5